{"id":"https://openalex.org/W12041443","doi":"https://doi.org/10.1096/fasebj.21.6.a787","title":"In Vitro pharmacology of N\u2010desmethylclozapine (ACP\u2010104) as compared to other atypical antipsychotic agents","display_name":"In Vitro pharmacology of N\u2010desmethylclozapine (ACP\u2010104) as compared to other atypical antipsychotic agents","publication_year":2007,"publication_date":"2007-01-01","ids":{"openalex":"https://openalex.org/W12041443","doi":"https://doi.org/10.1096/fasebj.21.6.a787","mag":"12041443"},"language":"en","primary_location":{"id":"doi:10.1096/fasebj.21.6.a787","doi":"https://doi.org/10.1096/fasebj.21.6.a787","is_oa":false,"landing_page_url":"https://doi.org/10.1096/fasebj.21.6.a787","pdf_url":null,"source":{"id":"https://openalex.org/S25293849","display_name":"The FASEB Journal","issn_l":"0892-6638","issn":["0892-6638","1530-6860"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The FASEB Journal","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5005645056","display_name":"Jelveh Lameh","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jelveh Lameh","raw_affiliation_strings":["Biosciences"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biosciences","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040662134","display_name":"Stefania Risso Bradley","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Stefania Risso Bradley","raw_affiliation_strings":["Biosciences"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biosciences","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5008619120","display_name":"Hans H. Schiffer","orcid":"https://orcid.org/0009-0008-7050-0816","observed_orcids":["https://orcid.org/0009-0008-7050-0816"]},"institutions":[{"id":"https://openalex.org/I125377440","display_name":"Acadia Pharmaceuticals (United States)","ror":"https://ror.org/030bhbq32","country_code":"US","type":"company","lineage":["https://openalex.org/I125377440"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hans H. Schiffer","raw_affiliation_strings":["TechnologyACADIA Pharmaceuticals3911 Sorrento Valley BlvdSan DiegoCA92121"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"TechnologyACADIA Pharmaceuticals3911 Sorrento Valley BlvdSan DiegoCA92121","institution_ids":["https://openalex.org/I125377440"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102339906","display_name":"Jian\u2010Nong Ma","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jian\u2010Nong Ma","raw_affiliation_strings":["Biosciences"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biosciences","institution_ids":[]}]},{"author_position":"middle","author":{"id":null,"display_name":"Thomas R. Ott","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Thomas R. Ott","raw_affiliation_strings":["Biosciences"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biosciences","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082960633","display_name":"Thomas Son","orcid":"https://orcid.org/0000-0001-7967-5980","observed_orcids":["https://orcid.org/0000-0001-7967-5980"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Thomas Son","raw_affiliation_strings":["Biosciences"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biosciences","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086982879","display_name":"Derek Nguyen","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Derek Nguyen","raw_affiliation_strings":["Biosciences"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biosciences","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053279288","display_name":"Ethan S. Burstein","orcid":"https://orcid.org/0000-0003-1120-9099","observed_orcids":["https://orcid.org/0000-0003-1120-9099"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ethan S. Burstein","raw_affiliation_strings":["Biosciences"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biosciences","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5070529034","display_name":"Douglas W. Bonhaus","orcid":"https://orcid.org/0000-0002-6567-2348","observed_orcids":["https://orcid.org/0000-0002-6567-2348"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Douglas W. Bonhaus","raw_affiliation_strings":["Biosciences"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biosciences","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":3740,"currency":"USD","value_usd":3740},"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.00174633,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"21","issue":"6","first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10023","display_name":"Schizophrenia research and treatment","score":0.9682999849319458,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10023","display_name":"Schizophrenia research and treatment","score":0.9682999849319458,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10056","display_name":"Neurotransmitter Receptor Influence on Behavior","score":0.020600000396370888,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11178","display_name":"Receptor Mechanisms and Signaling","score":0.002400000113993883,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/n-desmethylclozapine","display_name":"N-desmethylclozapine","score":0.9980000257492065},{"id":"https://openalex.org/keywords/clozapine-metabolites","display_name":"clozapine metabolites","score":0.9179999828338623},{"id":"https://openalex.org/keywords/atypical-antipsychotics","display_name":"atypical antipsychotics","score":0.9950000047683716},{"id":"https://openalex.org/keywords/schizophrenia","display_name":"schizophrenia","score":0.5540000200271606},{"id":"https://openalex.org/keywords/antipsychotic-side-effects","display_name":"antipsychotic adverse effects","score":0.6830000281333923},{"id":"https://openalex.org/keywords/procognitive-effects","display_name":"procognitive effects","score":0.5809999704360962},{"id":"https://openalex.org/keywords/receptor-binding-profiles","display_name":"receptor binding profiles","score":0.5450000166893005}],"concepts":[{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.7111420035362244},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.5813928842544556},{"id":"https://openalex.org/C2778938600","wikidata":"https://www.wikidata.org/wiki/Q389934","display_name":"Agonist","level":3,"score":0.5647594332695007},{"id":"https://openalex.org/C2780864610","wikidata":"https://www.wikidata.org/wiki/Q221361","display_name":"Clozapine","level":3,"score":0.5371831655502319},{"id":"https://openalex.org/C2780494398","wikidata":"https://www.wikidata.org/wiki/Q208144","display_name":"Antipsychotic","level":3,"score":0.5366878509521484},{"id":"https://openalex.org/C44208683","wikidata":"https://www.wikidata.org/wiki/Q15335165","display_name":"Dopamine receptor D2","level":3,"score":0.5246408581733704},{"id":"https://openalex.org/C58732023","wikidata":"https://www.wikidata.org/wiki/Q770260","display_name":"Partial agonist","level":4,"score":0.5085865259170532},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.4835398197174072},{"id":"https://openalex.org/C89951826","wikidata":"https://www.wikidata.org/wiki/Q1671731","display_name":"Inverse agonist","level":4,"score":0.4712695777416229},{"id":"https://openalex.org/C513476851","wikidata":"https://www.wikidata.org/wiki/Q170304","display_name":"Dopamine","level":2,"score":0.44903233647346497},{"id":"https://openalex.org/C38533456","wikidata":"https://www.wikidata.org/wiki/Q1671589","display_name":"Intrinsic activity","level":4,"score":0.44474682211875916},{"id":"https://openalex.org/C120069818","wikidata":"https://www.wikidata.org/wiki/Q415496","display_name":"Dopamine receptor","level":3,"score":0.43653666973114014},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.3915024995803833},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.2767815589904785},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.25682705640792847},{"id":"https://openalex.org/C2776412080","wikidata":"https://www.wikidata.org/wiki/Q7431605","display_name":"Schizophrenia (object-oriented programming)","level":2,"score":0.1522546410560608},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.07878640294075012},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.067973792552948},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.050346702337265015}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1096/fasebj.21.6.a787","doi":"https://doi.org/10.1096/fasebj.21.6.a787","is_oa":false,"landing_page_url":"https://doi.org/10.1096/fasebj.21.6.a787","pdf_url":null,"source":{"id":"https://openalex.org/S25293849","display_name":"The FASEB Journal","issn_l":"0892-6638","issn":["0892-6638","1530-6860"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The FASEB Journal","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9763000011444092}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W1989299632","https://openalex.org/W2260192576","https://openalex.org/W2063647140","https://openalex.org/W2046479063","https://openalex.org/W2011180752","https://openalex.org/W2046288000","https://openalex.org/W2327913641","https://openalex.org/W2075458309","https://openalex.org/W2055782708","https://openalex.org/W2062009247"],"abstract_inverted_index":{"Effective":[0],"treatment":[1],"with":[2,15,26,48,97],"antipsychotics":[3,126],"depends":[4],"on":[5,38],"the":[6,39,60,75],"balance":[7],"between":[8],"their":[9],"activities":[10],"at":[11,43],"multiple":[12],"receptors.":[13,45],"Interaction":[14],"serotonin":[16],"receptors":[17,31,174],"contributes":[18],"to":[19],"increased":[20],"efficacy":[21,99],"and":[22,29,53,72,100,133,149,159,171,183],"tolerability":[23,101],"while":[24],"interaction":[25,47],"dopamine":[27,130,151],"D2":[28],"muscarinic":[30,145],"could":[32],"be":[33,55],"therapeutic":[34],"or":[35],"detrimental":[36],"depending":[37],"level":[40],"of":[41,65,78],"activity":[42,64,96],"these":[44],"Finally,":[46],"\u03b1-adrenoceptors":[49],"causes":[50],"side":[51],"effects":[52],"should":[54],"avoided.":[56],"To":[57],"better":[58,160],"understand":[59],"molecular":[61],"basis":[62],"for":[63,84,168,179],"antipsychotics,":[66,71],"we":[67],"have":[68],"profiled":[69],"several":[70],"N-desmethylclozapine":[73],"(NDMC),":[74],"principle":[76],"metabolite":[77],"clozapine":[79],"(currently":[80],"in":[81],"clinical":[82],"development":[83],"schizophrenia":[85],"as":[86],"ACP-104).":[87],"NDMC":[88,127,142],"has":[89,165],"unique":[90],"pharmacological":[91],"features":[92],"that":[93],"suggest":[94],"antipsychotic":[95],"improved":[98],"(Weiner":[102],"et":[103,110,117],"al.":[104,111,118],"Psychopharm":[105],"177:":[106],",":[107,114,121],"2004;":[108],"Burstein":[109],"JPET":[112],"315:":[113],"2005;":[115],"Sur":[116],"PNAS":[119],"100:":[120],"2003).":[122],"Like":[123],"many":[124],"other":[125],"is":[128,143],"a":[129,134,144,176],"receptor":[131,147,152],"ligand":[132],"high":[135],"affinity":[136,167],"5-HT2A":[137],"antagonist/inverse":[138],"agonist.":[139],"However":[140],"uniquely,":[141],"M1":[146],"agonist":[148,154],"D2/D3":[150],"partial":[153],"suggesting":[155,175],"potential":[156,178],"procognitive":[157],"actions":[158],"motoric":[161],"tolerability.":[162],"Furthermore,":[163],"ACP-104":[164],"lower":[166,177],"alpha":[169],"adrenergic":[170],"histamine":[172],"H1":[173],"weight":[180],"gain,":[181],"sedation":[182],"orthostatic":[184],"hypotension.":[185]},"counts_by_year":[],"updated_date":"2026-10-12T09:40:04.860316","created_date":"2016-06-24T00:00:00"}